통증 관리 치료제 시장 : 약제 클래스별, 투여 경로, 적응증, 유통 채널, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Pain Management Therapeutics Market is projected to grow by USD 126.75 billion at a CAGR of 5.00% by 2032.

Pain Management Therapeutics Executive Summary

Pain management therapeutics are being reshaped by the global burden of chronic pain, aging populations, rising musculoskeletal disorders, cancer-related pain, postsurgical pain, neuropathic pain, and migraine. Verified public-health evidence underscores the scale: the U.S. CDC reported that 20.9% of U.S. adults experienced chronic pain in 2021, while the WHO and IASP recognize pain as a major driver of disability, reduced quality of life, and reduced functional capacity.

The market is moving beyond conventional opioid-centered care toward multimodal pain management, including nonsteroidal anti-inflammatory drugs, acetaminophen, anticonvulsants, antidepressants, topical analgesics, local anesthetics, biologics, neuromodulation-adjacent therapeutics, and digital pain support tools. Commercial success increasingly depends on demonstrating measurable outcomes, safety, real-world effectiveness, and alignment with opioid stewardship policies.

Transformative Shifts in the Pain Therapeutics Landscape

The pain management therapeutics landscape is undergoing a structural shift from symptom suppression to precision, evidence-led, and patient-specific treatment pathways. Regulators, payers, and clinicians are prioritizing non-opioid analgesics, abuse-deterrent formulations, safer prescribing protocols, and therapies that address neuropathic, inflammatory, nociplastic, and mixed pain mechanisms.

Scientific progress is also changing competitive positioning. CGRP-targeted migraine therapies, sodium-channel research, cannabinoid-based programs where permitted, extended-release local anesthetics, and repurposed neuromodulatory medicines are expanding the innovation pipeline. At the same time, formulary access is increasingly tied to comparative effectiveness, pharmacovigilance, and health-economic evidence rather than brand recognition alone.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across pain therapeutic discovery, clinical development, prescribing support, and patient monitoring. AI-enabled target identification, molecular screening, trial feasibility analytics, and real-world evidence mining can reduce uncertainty in identifying pain phenotypes and treatment-response patterns.

In clinical and commercial use, AI supports risk stratification for opioid misuse, adverse-event detection, dose optimization, and remote symptom tracking through digital health platforms. The impact is not a single disruption but an accumulating advantage: organizations that combine compliant data governance, validated algorithms, and clinician oversight can improve trial design, personalize therapy selection, and strengthen payer evidence packages.

Key Regional Insights for Pain Management Therapeutics

Asia-Pacific is becoming a high-priority arena for pain management therapeutics due to population scale, rapid aging in Japan, China, South Korea, and Australia, and expanding access to specialty care in India and Southeast Asia. Demand is supported by osteoarthritis, low back pain, diabetic neuropathy, migraine, cancer pain, and postsurgical pain, while affordability, reimbursement diversity, and local prescribing pathways continue to shape product uptake.

North America remains the most evidence-intensive and policy-sensitive region, led by the United States and Canada. The region combines high chronic pain prevalence, advanced specialty prescribing, strong adoption of migraine and biologic therapies, and rigorous opioid-risk controls. Latin America, led by Brazil and Mexico, is expanding access through public and private channels, though budget constraints, fragmented reimbursement, and uneven specialist availability influence adoption.

Europe is shaped by aging demographics, strong health technology assessment requirements, and country-specific reimbursement pathways across Germany, France, Italy, Spain, and the United Kingdom. The Middle East, particularly GCC health systems, is investing in hospital capacity, oncology care, and specialty clinics, supporting higher-value pain therapies with clear clinical evidence. Africa remains access-constrained but shows sustained need for affordable analgesics, palliative care medicines, essential pain education, and stronger supply continuity.

Key Economic and Strategic Group Insights

ASEAN markets show rising demand for affordable pain medicines, diabetic neuropathy treatment, migraine care, and postoperative pain control as healthcare coverage expands and chronic disease prevalence grows. Commercial strategies in the region require differentiated pricing, local partnerships, and education-led adoption because reimbursement, pharmacy access, and prescribing infrastructure differ widely among member states.

The GCC is increasingly aligned with specialty-care modernization, oncology investment, and hospital-based pain services, making it attractive for premium therapeutics with strong clinical evidence and safety profiles. The European Union is defined by regulatory harmonization through centralized and national procedures but commercial fragmentation through national HTA and reimbursement systems, requiring country-level evidence planning and early payer engagement.

BRICS countries represent large-volume access opportunities, with China, India, and Brazil offering population scale and Russia and South Africa contributing distinct affordability, procurement, and access dynamics. G7 markets remain the benchmark for innovation uptake, pharmacovigilance, controlled-substance oversight, and payer scrutiny. NATO countries overlap heavily with advanced European and North American systems, where supply security, controlled-medicine governance, and resilient pharmaceutical logistics are strategic priorities for pain management therapeutics.

Key Country Insights Across Priority Markets

The United States is the central market for pain management therapeutics due to high chronic pain prevalence, advanced specialist care, extensive clinical research activity, and strong regulatory attention to opioid stewardship. Canada follows similar safety priorities while emphasizing public reimbursement and evidence-based prescribing. Mexico and Brazil offer expanding access opportunities across branded generics, anti-inflammatory drugs, neuropathic pain medicines, migraine therapies, and hospital-based pain management.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are influenced by national health systems, HTA standards, and aging populations with a high musculoskeletal pain burden. Germany remains important for early European launch strategy, while France, Italy, and Spain require strong reimbursement dossiers and comparative clinical evidence. Russia presents demand for affordable and locally accessible pain therapies amid a complex regulatory, procurement, and operating environment.

China and India are major long-term priority markets because of population scale, diabetes-related neuropathy, cancer care expansion, musculoskeletal disease burden, and rising urban healthcare access. Japan has high demand associated with aging, osteoarthritis, neuropathic pain, postsurgical pain, and migraine management. Australia and South Korea offer sophisticated regulatory systems, high digital-health readiness, and opportunities for evidence-backed specialty therapies supported by real-world outcomes and clinician education.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated non-opioid and opioid-sparing portfolios supported by robust clinical endpoints, real-world evidence, and safety data. Development programs should segment patients by pain mechanism, comorbidities, functional impairment, and treatment history to improve trial success and payer relevance.

Organizations should invest in AI-enabled evidence generation, pharmacovigilance, and patient-reported outcome platforms while maintaining transparent governance and regulatory validation. Market access teams need region-specific reimbursement strategies, education programs for clinicians, and partnerships with health systems to support responsible prescribing, adherence, and measurable functional outcomes.

Research Methodology

The executive summary is based on structured secondary research and evidence triangulation using authoritative sources such as WHO, CDC, NIH, FDA, EMA, OECD health data, national health agencies, peer-reviewed journals, clinical trial registries, and public regulatory guidance. Insights were evaluated for relevance to therapeutic classes, disease burden, prescribing behavior, reimbursement, safety monitoring, and regional access conditions.

The methodology emphasizes verified public-health indicators, regulatory trends, clinical evidence, and commercially observable market dynamics. Qualitative interpretation was applied to identify strategic implications while avoiding unsupported market-size claims, market share estimates, or unverified projections.

Conclusion

Pain management therapeutics are entering a new phase defined by safety, personalization, non-opioid innovation, and evidence-based access. The market remains essential because chronic and acute pain continue to impose substantial clinical, economic, and social burden across developed and emerging healthcare systems.

Organizations that combine scientifically differentiated therapies, responsible opioid stewardship, AI-supported evidence generation, and region-specific commercialization will be best positioned to achieve sustainable competitiveness. The next advantage will come from proving not only analgesic efficacy but also functional improvement, safety, adherence, patient experience, and value for payers and patients.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pain Management Therapeutics Market, by Drug Class

• 7.1. Adjuvant Analgesics
• 7.2. Local Anesthetics
• 7.3. Neuropathic Pain Agents
  • 7.3.1. Anticonvulsants
  • 7.3.2. Antidepressants
• 7.4. Nonsteroidal Anti-Inflammatory Drugs
  • 7.4.1. Cox-2 Inhibitors
  • 7.4.2. Traditional NSAIDs
• 7.5. Opioids
  • 7.5.1. Strong Opioids
  • 7.5.2. Weak Opioids

8. Pain Management Therapeutics Market, by Route Of Administration

• 8.1. Oral
• 8.2. Parenteral
  • 8.2.1. Intramuscular
  • 8.2.2. Intravenous
  • 8.2.3. Subcutaneous
• 8.3. Topical
• 8.4. Transdermal

9. Pain Management Therapeutics Market, by Indication

• 9.1. Acute Pain
• 9.2. Chronic Pain
  • 9.2.1. Low Back Pain
  • 9.2.2. Neuropathic Chronic Pain
  • 9.2.3. Osteoarthritis
  • 9.2.4. Rheumatoid Arthritis
• 9.3. Inflammatory Pain
• 9.4. Neuropathic Pain

10. Pain Management Therapeutics Market, by Distribution Channel

• 10.1. Offline
• 10.2. Online

11. Pain Management Therapeutics Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Home Care Settings
  • 11.2.1. Hospice Care
  • 11.2.2. Patient Home
• 11.3. Hospitals
  • 11.3.1. Private Hospitals
  • 11.3.2. Public Hospitals

12. Pain Management Therapeutics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Pain Management Therapeutics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Pain Management Therapeutics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. AbbVie Inc.
• 16.3. Amgen Inc.
• 16.4. Assertio Holdings, Inc.
• 16.5. AstraZeneca plc
• 16.6. Aurobindo Pharma Limited
• 16.7. Bayer AG
• 16.8. Boston Scientific Corporation
• 16.9. Cipla Limited
• 16.10. Daiichi Sankyo Company, Limited
• 16.11. Dr. Reddy's Laboratories Limited
• 16.12. Eli Lilly and Company
• 16.13. Endo International plc
• 16.14. Fresenius Kabi AG
• 16.15. GlaxoSmithKline plc
• 16.16. Grunenthal GmbH
• 16.17. Hikma Pharmaceuticals PLC
• 16.18. Johnson & Johnson Services, Inc.
• 16.19. Kyowa Kirin Co., Ltd.
• 16.20. Lupin Limited
• 16.21. Mallinckrodt plc
• 16.22. Merck & Co., Inc.
• 16.23. Novartis AG
• 16.24. Pfizer Inc.
• 16.25. Purdue Pharma L.P.
• 16.26. Sanofi S.A.
• 16.27. Sun Pharmaceutical Industries Ltd.
• 16.28. Takeda Pharmaceutical Company Limited
• 16.29. Teva Pharmaceutical Industries Ltd.
• 16.30. Vertex Pharmaceuticals Incorporated
• 16.31. Viatris Inc.